General University Hospital Of Larissa

The medical center is at the forefront of research in Systemic Lupus Erythematosus, focusing on innovative therapies to manage and reduce disease activity. The center's work includes evaluating the long-term safety and efficacy of novel treatments, such as cenerimod and dapirolizumab pegol, which aim to improve patient outcomes by targeting specific pathways involved in the disease.

• Novel oral medications
• Long-term safety studies
• Combination therapies

These studies contribute significantly to understanding the disease mechanisms and developing more effective treatment protocols for SLE patients.

Research at the center is advancing the treatment of Non-Small Cell Lung Cancer through trials that explore the efficacy of targeted therapies and immunotherapy combinations. The focus is on improving survival rates and quality of life for patients with specific genetic mutations, such as KRAS G12C and EGFR Exon 20 insertions.

• Targeted therapy regimens
• Immunotherapy combinations
• Genetic mutation-specific treatments

These efforts are crucial in personalizing cancer treatment and enhancing therapeutic outcomes for NSCLC patients.

The center is pioneering research in Multiple Myeloma, focusing on maintenance therapies post-autologous stem cell transplant and novel drug combinations. Studies aim to improve progression-free survival and overall response rates, offering new hope for patients with newly diagnosed and relapsed conditions.

• Maintenance therapy comparisons
• Combination drug efficacy
• Progression-free survival improvement

These advancements are pivotal in extending the lives of multiple myeloma patients and enhancing their quality of life.

Innovative research at the center is focused on Muscle Invasive Bladder Cancer, exploring perioperative treatment strategies to improve event-free survival. The trials compare novel drug combinations with standard chemotherapy, aiming to enhance treatment efficacy and patient outcomes.

• Perioperative treatment strategies
• Event-free survival enhancement
• Comparative efficacy studies

This research is instrumental in developing more effective treatment protocols for bladder cancer patients.

The center is actively involved in addressing Post-Acute COVID Syndrome through clinical trials that assess the efficacy and safety of treatments like anakinra. These studies aim to alleviate persistent respiratory symptoms and improve the overall clinical state of affected patients.

• Respiratory symptom management
• Immunological state improvement
• Safety and efficacy evaluations

This research is vital in providing relief and improving the quality of life for patients suffering from long-term COVID-19 effects.

Research at the center is advancing the understanding and treatment of Primary Biliary Cholangitis through studies that evaluate the effects of drug combinations on disease markers. The focus is on improving patient outcomes by reducing disease progression and enhancing liver function.

• Drug combination efficacy
• Disease marker reduction
• Liver function improvement

These studies are crucial in developing more effective treatments for PBC, offering hope for better disease management.